How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?
  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
The content on this page is not current guidance and is only for the purposes of the consultation process.

2 Information about olaparib

Marketing authorisation

Olaparib (Lynparza, AstraZeneca) as tablets is indicated 'as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy'.

Dosage in the marketing authorisation

Olaparib is taken orally. It is currently available both in a tablet and a capsule formulation. However the capsule formulation is only licensed for people with BRCA mutation-positive platinum-sensitive ovarian cancer and will be phased out when no longer needed by patients. Therefore, only the tablets are covered by this appraisal because the company intends to phase out the capsules.

Dose of tablet formulation is 300 mg (2 x 150‑mg tablets) taken twice daily (600 mg per day).

Price

List price for tablets is £2,317.50 per 14-day pack; £4,635 per 28-day cycle (excluding VAT; British national formulary [BNF] online [accessed October, 2018]).